Literature DB >> 1567204

Localization of the type III isozyme of hexokinase at the nuclear periphery.

A Preller1, J E Wilson.   

Abstract

The distribution of the type III isozyme of hexokinase (ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1) in rat kidney, liver, spleen, lung, and brain was determined immunohistochemically, using a monoclonal antibody generated against the enzyme purified from rat Novikoff hepatoma. In all tissues, specific cell types exhibited intense staining at the nuclear periphery, as confirmed by analysis using confocal microscopy. Isolated nuclei from kidney or liver were devoid of detectable type III hexokinase, although the enzyme was found in the "soluble" fraction from kidney or liver homogenates; these results suggest that the type III isozyme is associated in a labile manner with the external surface of the nucleus, with this association being disrupted by conventional homogenization and nuclear isolation procedures. The nuclear localization of the type III isozyme contrasts with previously demonstrated association of the type I and II isozymes with mitochondria. The physiological significance of a nuclear localization for the type III isozyme remains unclear. However, it was noted that many of the cells exhibiting prominent nuclear staining for type III hexokinase are endothelial or epithelial cells, suggesting a possible relationship between nuclear type III hexokinase and transport functions which are prominent in such cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1567204     DOI: 10.1016/0003-9861(92)90715-9

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  13 in total

1.  Nucleocytoplasmic shuttling of hexokinase II in a cancer cell.

Authors:  Catherine L Neary; John G Pastorino
Journal:  Biochem Biophys Res Commun       Date:  2010-03-24       Impact factor: 3.575

2.  The regulatory protein of glucokinase binds to the hepatocyte matrix, but, unlike glucokinase, does not translocate during substrate stimulation.

Authors:  L Agius; M Peak; E Van Schaftingen
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

3.  Purification and characterization of the carboxyl-domain of human hexokinase type III expressed as fusion protein.

Authors:  F Palma; D Agostini; P Mason; M Dachà; G Piccoli; B Biagiarelli; M Fiorani; V Stocchi
Journal:  Mol Cell Biochem       Date:  1996-02-09       Impact factor: 3.396

Review 4.  Hexokinase binding to mitochondria: a basis for proliferative energy metabolism.

Authors:  S G Golshani-Hebroni; S P Bessman
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

5.  PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.

Authors:  Elena A Federzoni; Peter J M Valk; Bruce E Torbett; Torsten Haferlach; Bob Löwenberg; Martin F Fey; Mario P Tschan
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 6.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

7.  Mitochondrial VDAC and hexokinase together modulate plant programmed cell death.

Authors:  Ashwini Godbole; Ashvini Kumar Dubey; Palakolanu S Reddy; M Udayakumar; Mathew K Mathew
Journal:  Protoplasma       Date:  2012-12-18       Impact factor: 3.356

8.  Regulation and cytoprotective role of hexokinase III.

Authors:  Eugene Wyatt; Rongxue Wu; Wael Rabeh; Hee-Won Park; Mohsen Ghanefar; Hossein Ardehali
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

9.  Renal cortical hexokinase and pentose phosphate pathway activation through the EGFR/Akt signaling pathway in endotoxin-induced acute kidney injury.

Authors:  Joshua A Smith; L Jay Stallons; Rick G Schnellmann
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-02

10.  Spermatogenic cell-specific type 1 hexokinase is the predominant hexokinase in sperm.

Authors:  Noriko Nakamura; Haruna Shibata; Deborah A O'Brien; Chisato Mori; Edward M Eddy
Journal:  Mol Reprod Dev       Date:  2008-04       Impact factor: 2.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.